Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded a dedicated Locations section with New York as a site; the old New York Locations header was removed and the page updated to revision v3.3.3.SummaryDifference0.2%

- Check55 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page no longer displays the government funding status notice. All study details, locations, and eligibility criteria remain unchanged.SummaryDifference0.4%

- Check77 days agoChange DetectedNo significant changes detected between the previous and current page versions. The content and study details appear unchanged aside from minor layout tweaks.SummaryDifference0.4%

- Check105 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.